Freshly Financed CureVac Seeks Partner To Keep Up In mRNA
Executive Summary
German biopharmaceutical company CureVac, which secured $29.5m via a new financing round this week, talks to Scrip on the sidelines of the BIO-Europe partnering conference in Cologne about development plans for its mRNA cancer vaccine technology and its goals for 2017 – which include securing a new pharma partner.
You may also be interested in...
Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
Genentech, BioNTech Pact Aims To Make Targeted Cancer Vaccines
Genentech will tap expertise of privately-held BioNTech in a collaboration aimed at developing individually tailored vaccines for use against a broad range of cancers, which the duo says offers “a new treatment paradigm” for oncology.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.